TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01148277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Remifentnyl
Description: Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and fentanyl
Description: Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam anf fentanyl
Description: group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
Study: NCT01315262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
Study: NCT01733030

Intervention type: DRUG
Intervention: Seromycin
Description: 250 mg versus 500 mg versus placebo effects on conditioned fear generalization

Intervention type: DRUG
Intervention: Seromycin
Description: 250 mg versus 500 mg versus placebo effects on conditioned fear generalization

Intervention type: DRUG
Intervention: Seromycin

Intervention type: DRUG
Intervention: Seromycin
Study: NCT04082000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-DP-o-04
Description: BOL-DP-o-04

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00294112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochymal™ adult human mesenchymal stem cells
Description: Cells in plasmalyte and containing dimethylsulfoxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochymal™ adult human mesenchymal stem cells
Description: Cells in plasmalyte and containing dimethylsulfoxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adult human mesenchymal stem cells
Description: two infusions, one week apart, each comprising adult human mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adult human mesenchymal stem cells
Description: two infusions, one week apart, each comprising adult human mesenchymal stem cells
Study: NCT01844895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Study: NCT00955630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 3 monthly injections of ranibizumab followed by prn injections for the remainder of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: prn injections of ranibizumab throughout the study
Study: NCT02851914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricyclic Antidepressants (TCA)
Description: if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective Serotonin Uptake Inhibitors (SSRI)
Description: if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
Study: NCT02757170

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thromboelastography
Description: Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thromboelastography
Description: Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thromboelastography
Description: Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thromboelastography
Description: Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
Study: NCT01979341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: final oocyte maturation trigger
Description: when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
Study: NCT03596372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834942
Description: Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834942
Description: Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834942
Description: Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834942
Description: Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834942
Description: Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part.
Study: NCT03515109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Altis tape
Description: placement of Altis tape through transobturator foramen bilaterally under epidural anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TVTO
Description: placement of TVTO tape through transobturator foarmen bilaterally under epidural anesthesia
Study: NCT00855114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 5 mg/day x 7 days by mouth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Definitive excision of breast cancer tissue
Study: NCT01403337

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic preconditioning
Description: The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP \> 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A Blood Pressure cuff inflated to 40-50 mmHg
Study: NCT02349178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
Study: NCT03400722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris
Description: Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
Study: NCT01088581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant group
Description: Adjuvant chemotherapy (5FU and cisplatin) after resection
Study: NCT01509352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophageal stitches during fundoplication
Description: placement of esophageal stitches with fundoplication

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no esophageal stitches placed during fundoplication
Description: no esophageal stitches are placed during the fundoplication procedure
Study: NCT02448511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
Study: NCT02986230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CP-CDS
Description: The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CP-CDS
Description: The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
Study: NCT02989792

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling for genotyping
Description: Venous punction of maximum 10 millilitres

Intervention type: OTHER
Group type: OTHER
Intervention: Personality Questionnaires completion
Description: Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
Study: NCT01318044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Thiopental
Description: An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Thiopental
Description: An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved
Study: NCT00603915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m\^2 intravenous (IV) day 1 and day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Cisplatin
Description: Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150mg daily (post GC therapy)
Study: NCT00758472

Intervention type: DEVICE
Intervention: ReCap Total Hip Resurfacing
Description: ReCap Total Hip Resurfacing
Study: NCT01031914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paced Breathing
Description: The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
Study: NCT03686501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two \[18F\]MNI-968 injections
Study: NCT01145066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: borage/echium oil combination
Description: borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 1.6g/day EPA and 1.08g/day DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: contains 4.5 g/day linoleic acid
Study: NCT01182428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V®/ XIENCE PRIME™
Description: Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER SELECT
Description: XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
Study: NCT03240146

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed Shortwave Therapy
Description: Pulsed Shortwave Therapy device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Shortwave Therapy
Description: Pulsed Shortwave Therapy device
Study: NCT01009476

Intervention type: DRUG
Intervention: Galantamine
Description: Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.

Intervention type: DRUG
Intervention: Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
Description: Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
Study: NCT01282229

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LANAP
Description: Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
Study: NCT00802685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early ibuprofen
Description: IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen.

Intervention type: OTHER
Group type: OTHER
Intervention: Late ibuprofen expectant group (placebo)
Description: Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV.
Study: NCT00428597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: * sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~* Dose may be decreased to 25 mg daily in case of adverse events.~* It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~* Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
Study: NCT00983047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab and Docetaxel
Description: The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab and Docetaxel
Description: The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity.
Study: NCT03370497

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Mineral Supplement
Description: Milk Minerals containing 1000 mg calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Hydrolysate
Description: 50 g whey protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate
Description: 50 g whey protein hydrolysate
Study: NCT02126085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular recanalisation
Description: Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular recanalisation
Description: Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept
Study: NCT03589404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rso2
Description: The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study: NCT01132209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the abdominal wall after midline incisions
Description: Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of the abdominal wall after midline incisions
Description: Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
Study: NCT02095743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implanted port for chemo administration (X-port isp)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of a PICC line for chemo administration (PowerPICC SOLO²)
Description: The description of the device could found on the published marketing authorisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a PICC line for chemo administration (PowerPICC SOLO²)
Description: The description of the device could found on the published marketing authorisation
Study: NCT04285567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.